Researchers at the National Institute of Environmental Health Sciences (NIEHS), Vanderbilt University Medical Center, and the Henry Ford Health System analyzed patient data from African-American women aged 23 to 35 years (N=1553) who were participating in the NIEHS Study of Environment, Lifestyle, and Fibroids (SELF).
The sublingual formulation of sufentanil offers a new treatment option for patients with nothing by mouth (NPO) status and patients with difficult IV access.
The 23andMe Personal Genome Service Pharmacogenetic Reports test can detect 33 variants for multiple genes, corresponding to more than 50 commonly prescribed medications and over-the-counter products.
Oliceridine, a G-protein biased mu-opioid receptor (MOR) ligand, has a unique mechanism of action that allows for more selective pathway activation while avoiding a pathway associated with opioid-related adverse events.
The non-aqueous adhesive patch requires 36mg per topical system to achieve the same therapeutic dose as Lidoderm (lidocaine 5%) which contains 700mg per patch.
Cassipa combines buprenorphine, an opioid (partial agonist-antagonist), and naloxone, an opioid antagonist.
The primary efficacy endpoint was the mean change from baseline in the monthly average number of headache days of at least moderate severity during the 3-month treatment period.
CA-008 is given as a single local injection and works by selectively desensitizing pain-conducting nerve fibers without causing numbness or weakness
Tests revealed Neuroveen to be contaminated with Staphylococcus saprophyticus and Burkholderia cepacia. Compulsin was also tested and found to contain B. cepacia.
The recalled product has Lot #R51129 (NDC 0573-0207-30) and was shipped to wholesalers, distributors, and retailers from May through June 2018.
